Publications by authors named "Carles M Rudin"
Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma.
J Clin Endocrinol Metab
September 2024
Article Synopsis
- Seizure-related 6 homolog (SEZ6) is linked to neuroendocrine differentiation and has been found to be highly expressed in medullary thyroid carcinoma (MTC), as well as small cell lung carcinoma (SCLC).
- A novel antibody drug, ABBV-011, targeting SEZ6 is currently in clinical trials for treating SCLC and neuroendocrine neoplasms, suggesting potential therapeutic applications.
- SEZ6 shows high immunoexpression in a majority of MTC cases, making it a promising biomarker, even though it does not correlate with patient outcomes or certain mutations, highlighting its potential for targeted therapy.